Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05842174 · ClinicalTrials.gov registry record · Phase 1
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
A Phase 1 study, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT05842174: Recruiting Phase 1 study, sponsored by VA Office of Research and Development.
NCT05842174 is a Phase 1 study that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05842174, a Phase 1 study, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then blocking the artery with embolics in order to kill tumor cells by depriving them of essential oxygen and nutrients. While TACE has a proven survival benefit, local recurrence is common, and long-term survival rates are poor. Prior studies demonstrate that HCC cells survive the oxygen and nutrient deprivation through autophagy, a process of cellular self-eating, to provide nutrients required for survival. The proposed project will leverage this dependency to develop a novel approach to TACE that integrates autophagy inhibition to improve therapeutic response by increasing tumor cell killing and enhancing anti-tumor immunity.
Interventions
- DRUG Placebo
- DRUG Hydroxychloroquine
- DRUG Lipiodol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2030-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05842174
The ClinicalTrials.gov registry entry for NCT05842174 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05842174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05842174 about?
NCT05842174 is a clinical study titled "Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma". Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and then...
What is the current status of trial NCT05842174?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2026-04-01. Estimated completion is 2030-10-15.
What interventions are being tested in trial NCT05842174?
The interventions under investigation include: Placebo (DRUG), Hydroxychloroquine (DRUG), Lipiodol (DRUG).
Who is sponsoring clinical trial NCT05842174?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.